Related references
Note: Only part of the references are listed.Dual Allosteric Inhibition of SHP2 Phosphatase
Michelle Fodor et al.
ACS CHEMICAL BIOLOGY (2018)
Off-target inhibition by active site-targeting SHP2 inhibitors
Ryouhei Tsutsumi et al.
FEBS OPEN BIO (2018)
Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases
Zhong-Yin Zhang
ACCOUNTS OF CHEMICAL RESEARCH (2017)
Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2
Jonathan R. LaRochelle et al.
BIOCHEMISTRY (2016)
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Jorge Garcia Fortanet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
WGE: a CRISPR database for genome engineering
Alex Hodgkins et al.
BIOINFORMATICS (2015)
Functions of Shp2 in cancer
Jie Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
Anirudh Prahallad et al.
CELL REPORTS (2015)
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
Jing Li et al.
CANCER RESEARCH (2015)
Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
Li-Fan Zeng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER
Oliver S. Smart et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2012)
New developments in the ATSAS program package for small-angle scattering data analysis
Maxim V. Petoukhov et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2012)
Crystal Structure of Human Protein Tyrosine Phosphatase SHP-1 in the Open Conformation
Wei Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Gordon Chan et al.
CANCER AND METASTASIS REVIEWS (2008)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
MG Mohi et al.
CANCER CELL (2005)
Liquid-chromatography-coupled SAXS for accurate sizing of aggregating proteins
E Mathew et al.
JOURNAL OF SYNCHROTRON RADIATION (2004)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
BG Neel et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Share Paper
